Technology Transfer and Entrepreneurship (Discontinued) - Current Issue

Targeted Protein Degradation (TPD) is an emerging new modality of drug discovery that offers unprecedented therapeutic benefits over traditional protein inhibition. Most importantly, TPD unlocks the untapped pool of the proteome that to date has been considered undruggable. Captor Therapeutics (Captor) is the fourth global, and first European, company that develops small molecule drug candidates based on the prin Read More

The Polish Life Science sector has been growing for the last decade and has received billions of euros in EU funding, but has still failed to attract significant private investment. Despite the EU financing, there are still no real market or investment success stories, although companies are emerging with the potential to be globally competitive. This article examines the financing and behaviour of the Polish Life Science secto Read More

Organizations managing technology transfer from universities to the private sector, although born in Poland with a significant delay compared to Western European countries, are currently important actors in the Polish innovation system. The article summarizes the process of shaping the role and models of the functioning of these organizations. It discusses the status and functions of technology transfer centers and the institut Read More

Ryvu Therapeutics and Selvita originated in 2007, a time when drug discovery in Poland was still not pursued by industrial enterprises. For many years, both entities operated one company and were known under a common name Selvita S.A., combining their efforts on both innovative small-molecule therapeutics for oncology and expertise in Contract Research Services (CRO). Following more than a decade of such a hybrid b Read More

The present article is a case study of a Polish biopharmaceutical company, “Pure Biologics”. The company was founded in 2010 by a group of scientists and, over the last nine years, grew substantially from just a few individuals to nearly one hundred professionals. Initially, a privately-funded civil partnership, Pure Biologics, has been transformed into a publicly-traded company. Such a transformation has been possible Read More

Jagiellonian University (JU) is one of the top universities in Central and Eastern Europe. Several faculties of the university are conducting research in the life sciences area. These projects include both direct drug discovery and development activities as well as research aimed at the creation of novel technologies with significant commercial potential. The present case study is based on a series of examples illustrating the cooper Read More

OncoArendi Therapeutics SA (OAT) has been founded in 2012 as USstyle biotech operating in Poland. From the beginning, OAT has been focused on first-in-class or best-in-class programs involving interactions with novel targets with no clinical validation. The experienced group of founders thought that Poland offered an abundance of young talent and non-dilutive financing from European and national grants and subsidies, Read More

The aim of this paper is to give an overview of the current state of technology transfer in Poland by examining various stages of the process and indicators associated with different actors involved. In order to examine the role of technology in polish enterprises, it takes into account different forms of intellectual property, both created and acquired in Poland. Data taken into consideration include domestic and external sources Read More